News

SUCCESS IN THE CHANGING HEALTH LANDSCAPE - OPTIMISING YOUR ORGANISATION

 “Equity and Excellence: Liberating the NHS” - after a noisy reception, much volatile debate and considerable revision the Bill quietly attained Royal Assent in March '12. The organisational changes in the NHS will require radical new approaches for all NHS suppliers, care providers, commissioning bodies, local Government and patient support groups. The introduction of Value Based Pricing, for pharmaceuticals and changes in NICE to include social care and wider social costs will also create new challenges with market access and launches.

 The new Secretary of State for Health, Jeremy Hunt, has set new priorities for the NHS – Improving Survival Rates and Outcomes; Improving Chronic Disease Care – Dementia, Diabetes etc; Improving the quality of clinical and customer Care; Better use of IT

 The NHS Commissioning Board has published ‘Everyone Counts: Planning for Patients’ with Higher Standards and Safer Care as the goal through – More [ patient] Choice and Improved Patient Outcomes. Health Providers will become more accountable, outcomes more transparent down to consultant level and patient will be asked if they would recommend the care they received to their family and friends.

Organisational Changes

  • Clinical Commissioning Groups (CCGs) will take over responsibility from PCTs in April '13.
  • Monitor has enhanced powers as the economic and competition regulator of the NHS.
  • NICE sees its powers extended to social care and will include wider social costs in its appraisals and reviews.
  • The NHS Commissioning Board will manage the NHS and specialist commissioning. CCGs will commission services locally and l be held financially accountable and responsible for delivering outcomes for patents.
  • Health and Wellbeing Boards in local Government will be responsible for public health and will work with CCGs and Healthwatch (representing patients and the public) to develop seamless health and social care for their local populations. There will be more local democratic accountability for healthcare.
  • There are new opportunities for the independent and private sectors in commissioning, managing NHS organisations and as healthcare providers.
  • All NHS Trusts will need to become FTs and will seek to expand their services.

Do you understand the details and implications of these changes to your organisation?

Have you identified your new stakeholders, customers and decision makers and began to develop new relationships?

Have you reviewed your structure, strategies and approaches to optimise success in the new NHS landscape?

Are your employees aware of what is happening and how this will affect their roles?

How will you gain successful market access for your new medicine or technology?

Will the new structure and processes mean new hurdles?

How will commissioning be changed and affected?

As the NHS changes suppliers will need to understand the implications and the changes they need to make to be successful. How we can help?

Value-Based Pricing, NICE and Market Access

The Health Select Committee has criticised “the delay in setting out precisely what a value-based pricing system for drugs entails” and has urged DH and the Government to make decisions by the end of March 2013.

Value-based pricing is likely to be introduced on new medicines from 2014, but some already on the market may also be reviewed. Understanding and communicating value will be key to successfully marketing products, growing the business and managing pipeline in the new environment. How are you preparing for this change?

What changes will be needed pre-launch to generate 'value' and social costs?

Do you know what value your products are to patients, the NHS and health economists?

What are the social costs of a treatment? How should these be assessed?

Can you demonstrate value for populations rather than just at individual patient level?

Market Access

The reorganisation to CCGs has changed personnel, responsibility and accountability, networks and commissioners. Although commissioners are made aware of new medicines there is no mechanism for new devices, technologies, consumable or capital equipment.

 Have you identified the new stakeholders and decision-makers you need influence to have your new product, service or treatment commissioned?

What new mechanisms and evidence will you need to influence and inform them?

Are you ready to look at new ways to manage more rigid formularies and trading agreements?

Do you understand how CQUIN (Commissioning for Quality and Innovation), Service Line Reporting and Best Practice Tariffs can help you communicate value?

Do you understand how Personalised Budgets and the quality agenda can help you deliver quality medicines to patients? How we can help?

 Planning for Patients

“No decision about me without me”-

  • Patients will have choice of their hospital, their consultant team and their GP
  • Patients will be fully informed about their treatment options and be able to make choices about the treatment most appropriate to them
  • Patients will have access to mortality, morbidity and outcomes data to inform their choices
  • NHS providers will be rated by patients on if they would recommend the care they received to their family and friends.

Why should patients choose your hospital or GP practice? How can you influence their choice?

Do patients know what services and treatments your organisation provides?

Are you providing the level of customer care your patients want?

How will you be rated by patients? What can you do about it?

How will you involve patients in service redesign and setting care standards?

Are you staff ready for the changes your organisation needs?

How can we help?

How we can help ?

Working with you we interpret the impact of the NHS changes on your organisation, marketing, sales and market access strategies and functions.

We offer an insight for all the levels within your organisation -

Board and Executive Level -

  • Strategic Updates - Executive workshops
  • Organisation and strategy review
  • Strategic business planning
  • Stakeholder mapping
  • Brand value evidence for pricing

 Senior Marketing and Market Access

  • Strategic Updates - senior management workshops
  • Brand portfolio review
  • Brand stakeholder mapping
  • Market access stakeholder mapping
  • In-depth stakeholder insight research/surveys
  • Brand strategy reviews
  • Market access strategy reviews
  • Brand value evidence for pricing

Sales and Market Access Teams

  • NHS update - training workshop
  • Tactical sales and market access reviews

Delivered by an experienced team of senior industry and NHS consultants Strategic Health Insights can help you address the strategic and operational challenges ahead. If you would like to know more contact

Ginette Camps-Walsh

07768 794061

How can we help NHS organisations?

Working with you we interpret the impact of the NHS changes on your organisational from board through to grassroots.

We offer an insight for all the levels within your organisation -

Board and Executive Level -

  • Strategic Updates - Executive workshops
  • Organisation and strategy review
  • Strategic business planning
  • Stakeholder mapping
  • Patient and public reception, engagement and true involvement

 Senior Management and Clinical Specialities

  • Strategic Updates and reviews - senior management workshops
  • Speciality portfolio review
  • In-depth stakeholder insight research/surveys, engagement and involvement
  • Staff change management training and workshops
  • Communications review for public and patients engagement and involvement

Delivered by an experienced team of senior industry and NHS consultants Strategic Health Insights can help you address the strategic and operational challenges ahead. If you would like to know more contact

Ginette Camps-Walsh

07768 794061